Oblenio Bio secured $62 million in a Series B to move its trispecific T-cell engager LBL-051 into first-in-human testing for chronic autoimmune diseases. The funding came roughly a year and a half after the company’s formation, following positive nonhuman primate data. The company’s reported preclinical package supported advancing the molecule into early clinical development, with the trispecific format designed to engage immune pathways through multiple mechanisms. Oblenio said it intends to use the capital to support clinical execution and operational ramp-up around the IND trajectory. Why it matters: tri-/multi-specific T-cell engager formats are being aggressively evaluated across autoimmune indications, and scale-up in early clinical programs often signals confidence that preclinical efficacy and tolerability translate into patient-relevant windows.